FORMULATION AND EVALUATION OF NANOSTRUCTURED LIPID CARRIERS BASED ANTI-INFLAMMATORY GEL FOR TOPICAL DRUG DELIVERY SYSTEM

ROHINI S KHARWADE; NILESH M MAHAJAN

doi:10.22159/ajpcr.2019.v12i4.32000

Authors

ROHINI S KHARWADE Department of , Dadasaheb Balpande College of Pharmacy, Besa, Nagpur, Maharashtra India.
NILESH M MAHAJAN Department of Pharmaceutical Sciences, Rashtrasant Tukadoji Maharaj Nagpur University, Nagpur, Maharashtra India.

DOI:

https://doi.org/10.22159/ajpcr.2019.v12i4.32000

Keywords:

Keywords, Nanolipidcarrier, Lornoxicam, Response surface methodology, Topical gel

Abstract

Objective: Nanostructured lipid carrier (NLC)-based topical gel of lornoxicam (LXM) was formulated with the aim of controlled release action and to reduce systemic side effect for the treatment of an arthritic condition.

Methods: NLCs developed using high-pressure homogenization method and optimized using a 32 factorial design with response surface methodology using design expert software. NLCs were characterized for particle size, zeta potential analysis, drug entrapment efficiency, and in vitro drug release studies to select the optimized formulation. The NLCs were suitably gelled and evaluated with respect to homogeneity, pH, viscosity, gel strength, spreadability, rheological characteristics, drug content, in vitro diffusion, and stability study. Safety of the NLC-based gel was assessed using primary skin irritation studies, and efficacy was confirmed using carrageenan-induced rat paw edema model.

Results: NLCs formulation comprising 2% of lipid (60:40) and surfactant (1.50%) was confirmed as an optimized batch having a particle size (138.2±3.60 nm) with polydispersibility index value 0.344±0.034. The zeta potential value indicates good physical stability. Based on the results from the in vitro release study it was shown that the formed gels had the ability to extend release of LXM for 24 h and showing percentage drug release of 90.92%±1.96% at the end of 24 h. Skin irritation studies revealed that the optimized gel formulation shows no erythema, edema, or ulceration.

Conclusion: The overall results of the present study clearly indicated promising potentials of NLC-based gel for delivering LXM topically over the conventional gel.

Downloads

Download data is not yet available.

Author Biography

ROHINI S KHARWADE, Department of , Dadasaheb Balpande College of Pharmacy, Besa, Nagpur, Maharashtra India.

pharmaceutics ( formulation and Evaluation)

References

Brigger C, Dubernet P. Nanoparticles in cancer therapy and diagnosis. Adv Drug Deliv 2002;54:631-51.

Abather A, Sadiq A, Abdul R. Formulation and evaluation of silibinin loaded solid lipid nanoparticles for peroral use targeting lower part of gastrointestinal tract. Int J Pharm Pharm Sci 2014;6:55-67.

Ajialex R, Chacko J, Jose S, Souto B. Lopinavir loaded solid lipid nanoparticles (SLN) for intestinal lymphatic targeting. Eur J Pharm Sci 2011;42:11-8.

Muller H. Solid-liquid (semi-solid) lipid particles and method of producing highly concentrated lipid particle dispersions. Eur Pat Appl 2000;45:199-203.

Muller R, Wissing A, Kayser O. Solid lipid nanoparticles for parenteral drug delivery. Adv Drug Deliv Rev 2004;56:1257-72.

Araujo J, Gonzalez E, Egea A, Garcia L, Souto B. Optimization and physicochemical characterization of a triamcinolone acetonide loaded NLC for ocular antiangiogenic applications. Int J Pharm Sci 2010; 393:167-75.

Senthil P, Arivuchelvan A, Jagadeeswaran A, Subramanian N, Senthil C, Mekala P. Formulation, optimization and evaluation of enrofloxacin solid lipid nanoparticles for sustained oral delivery. Asian J Pharm Clin Res 2015;8:231-6.

Panchaxari M, Dandagi G, Dessai A, Gadad V. Formulation and evaluation of nanostructured lipid carrier (NLC) of lornoxicam. Int J Pharm Pharm Sci 2014;6:198-210.

Muchow M, Maincent P, Muller H. Lipid nanoparticles with a solid matrix (SLN®, NLC®, LDC®) for oral drug delivery. Drug Dev Ind Pharm 2008;34:1394-405.

Chalikwar S, Belgamwar V, Talele R, Surana S, Patil M. Formulation and evaluation of nimodipine-loaded solid lipid nanoparticles delivered via lymphatic transport system. Coll Sur Bioint 2012;97:109-6.

Singh H, Gupta RD, Gautam G. Formulation development, characterization, and in vitro-in vivo study of antihyperlipidemic drug rosuvastatin calcium-solid lipid nano particles. Asian J Pharm Clin Res 2018;11:436-43.

Nanjwade B, Kadam V, Manvi F. Formulation and characterization of nanostructured lipid carrier of ubiquinone (Coenzyme Q10). J Biom Nanotech 2013;9:450-60.

Hu F, Jiang S, Du Y, Zeng S. Preparation and characterization of stearic acid nanostructured lipid carriers by solvent diffusion method in an aqueous system. Coll Sur Bioint 2005;45:167-73.

Zhang X, Liu J, Liu H, Ni J, Zhang W, Qiao H, et al. Formulation and optimization of dihydroartemisinin nanostructured lipid carries using response surface methodology. Powder Tech 2010;197:120-8.

Venkateswarlu V, Manjunath K. Preparation, characterization and in vitro release kinetics of clozapine solid lipid nanoparticles. J Contact Rel 2004;95:627-38.

Asmin B, Reddy P. Formulation and evaluation of dasatinib loaded solid lipid nanoparticles. Int J Pharm Pharm Sci 2018;10:14-20.

Kesharwani R, Sachan A, Singh S, Patel D. Formulation and evaluation of solid lipid nanoparticle based topical gel of etoricoxib. J App Pharm Sci 2016;6:124-31.

Montenegro L, Campisi A, Sarpietro M, Carbone C, Acquaviva R, Raciti G, et al. In vitro evaluation of idebenone-loaded solid lipid nanoparticles for drug delivery to the brain. Drug Dev Ind Pharm 2011; 37:737-47.

Singh S, Singh S, Sharma A, Kaur D, Katual M. Formulation and in-vitro evaluation of solid lipid nanoparticles containing levosulpiride. Open Nanomed J 2017;4:17-29.